Drug

Aflibercept

Approved · EMA

ClassVascular endothelial growth factor A inhibitorEmerging researchLate-stage developmentCooling momentum

Also known as Ahzantive, Eydenzelt, Eylea, Opuviz+2 more

Ahzantive, Eydenzelt, Eylea, Opuviz, Pavblu, Zaltrap.

RxNorm1232150 ChEMBLCHEMBL1742982 ATCL01XX44 ATCS01LA05UNII15C2VL427D

Research papers

Active clinical trials

Protein targets

Regulatory events

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Three-arm Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal Tarcocimab Tedromer and Tabirafusp Tedromer Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)

Clinical trial2026-08-01Primary completion · ClinicalTrials.gov

A Randomized Double-masked, Multicenter, 3-arm, Pivotal Phase 2/3 Study to Evaluate the Efficacy and Safety of Intravitreal (IVT) EYE201/MK-8748 Compared to Aflibercept (2 mg) in Participants With Neovascular Age-related Macular Degeneration (NVAMD)

Clinical trial2026-07-24Results expected Q2 2028 · ClinicalTrials.gov

A Multi-center, Randomized, Double-masked, Active-comparator-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)

Clinical trial2026-07-15Results expected Q4 2027 · ClinicalTrials.gov

A Randomized, Double-masked, Comparative Clinical Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 938 8 mg Versus EYLEA® HD (Aflibercept) Delivered Via Intravitreal Injection in Participants With Neovascular Age-related Macular Degeneration

Clinical trial2026-07-10Results expected Q3 2027 · ClinicalTrials.gov

Approval: Eyluxvi (EMA)

Regulatory2025-09-15EMA

Approval: Afiveg (EMA)

Regulatory2025-08-18EMA

Approval: Mynzepli (EMA)

Regulatory2025-08-18EMA

Approval: Eiyzey (EMA)

Regulatory2025-08-14EMA

First-Line LV5FU2 with or without Aflibercept in Patients with Non-Resectable Metastatic Colorectal Cancer: A Randomized Phase II Trial (PRODIGE 25-FFCD-FOLFA).

Research2024-04-16Cancers

Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.

Research2022-01-24Lancet (London, England)

Aflibercept in Combination With FOLFIRI as First-line Chemotherapy in Patients With Metastatic Colorectal Cancer (mCRC): A Phase II Study (FFCD 1302).

Research2020-06-12Clinical colorectal cancer

Anti-Vascular Endothelial Growth Factors Protect Retinal Pigment Epithelium Cells Against Oxidation by Modulating Nitric Oxide Release and Autophagy.

Research2017-07-25Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Aflibercept

Aliases & brands

AhzantiveEydenzeltEyleaOpuvizPavbluZaltrap

RxNorm CUI

1232150

ChEMBL ID

CHEMBL1742982

ATC codes

L01XX44S01LA05

UNII

15C2VL427D

Primary mechanism

Vascular endothelial growth factor A inhibitor

Regulatory jurisdictions

fdaemamhra

Pharmacology & targets

2 targets

Known molecular targets and mechanisms supported by curated pharmacology databases.

Vascular endothelial growth factor A, long form

VEGFA · P15692

INHIBITORVascular endothelial growth factor A inhibitor

Placenta growth factor

PGF · P49763

INHIBITORPlacenta growth factor inhibitor

Regulatory timeline

15 events

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval

2012-11-21

Latest approval

2025-09-15

Authorities

FDA · EMA · MHRA

Total events

fdaU.S. Food and Drug Administration· 1 event

2024-05-15RecallSafety

Recall (Class II): AFLIBERCEPT

Evidence ↗

emaEuropean Medicines Agency· 13 events

2025-09-15Approval

Approval: Eyluxvi (EMA)

Indication: Eyluxvi is indicated for adults for the treatment of- neovascular (wet) age-related macular degeneration (AMD) (see section 5.1),- visual impairment due to macular oedema… Show full indication

Eyluxvi is indicated for adults for the treatment of- neovascular (wet) age-related macular degeneration (AMD) (see section 5.1),- visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) (see section 5.1),- visual impairment due to diabetic macular oedema (DME) (see section 5.1),- visual impairment due to myopic choroidal neovascularisation (myopic CNV) (see section 5.1). 

Evidence ↗

2025-08-18Approval

Approval: Afiveg (EMA)

Indication: Afiveg is indicated for adults for the treatment of neovascular (wet) age-related macular degeneration (AMD) (see section 1), visual impairment due to macular oedema secondary to… Show full indication

Afiveg is indicated for adults for the treatment of neovascular (wet) age-related macular degeneration (AMD) (see section 1), visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) (see section 5.1), visual impairment due to diabetic macular oedema (DME) (see section1), visual impairment due to myopic choroidal neovascularisation (myopic CNV) (see section 5.1).

Evidence ↗

2025-08-18Approval

Approval: Mynzepli (EMA)

Indication: Mynzepli is indicated for adults for the treatment of- neovascular (wet) age-related macular degeneration (AMD),- visual impairment due to macular oedema secondary to retinal vein… Show full indication

Mynzepli is indicated for adults for the treatment of- neovascular (wet) age-related macular degeneration (AMD),- visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO),- visual impairment due to diabetic macular oedema (DME),- visual impairment due to myopic choroidal neovascularisation (myopic CNV)

Evidence ↗

mhraMedicines and Healthcare products Regulatory Agency· 1 event

2016-04-18Safety communicationSafety

Drug Safety Update: Aflibercept (Zaltrap▼): minimising the risk of osteonecrosis of the jaw

Evidence ↗

Data from the U.S. Food and Drug Administration (U.S. Food and Drug Administration), public domain (CC0).

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.

Contains public sector information from the Medicines and Healthcare products Regulatory Agency (MHRA) licensed under the Open Government Licence (OGL v3).

Clinical trials

185 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme

CLINICALTRIALS.GOV · LIVE REGISTRY

185

registered trials across all phases

LATEST COMPLETION 2026

Active studies

Recruiting

116

Late-stage (III+)

110

Completed

Discontinued

PHASE DISTRIBUTIONn = 185

Early Phase 12Phase 114Phase 1 / 28Phase 245Phase 2 / 34Phase 352Phase 448Phase N / A12

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

A 96-week, Single-arm Study to Evaluate the Efficacy and Safety of 8mg Aflibercept in Subjects With Proliferative Diabetic Retinopathy (PDR) Without Center-involved Diabetic Macular Edema (DME)

Active, not recruitingPH IVEdward Wood, MDn=402028

A Randomised Controlled Trial Comparing Efficacy of Single Versus Multiple Intravitreal Anti-VEGF Injections to Prevent Diabetic Retinopathy Progression in Patients Undergoing Cataract Surgery

Not yet recruitingPH IVAhmad Zeeshan Jamiln=1662026

Efficacy of Switching to Aflibercept 8mg in Patients With Neovascular AMD Showing Limited Response to Faricimab or Aflibercept 2mg

RecruitingPH IVKim's Eye Hospitaln=402026

An Open-label, Non-randomized, Multi-center, Phase 4 Pharmacokinetic Study to Evaluate the Systemic Exposure After Bilateral Intravitreal Administration of High Dose (8 mg) Aflibercept in Adults With Diabetic Macular Edema or Neovascular Age-related Macular Degeneration

CompletedPH IVBayern=512025

A Randomized, Masked, Controlled Study of Intravitreal ILUVIEN® Implant as Baseline Therapy in Patients With Early Diabetic Macular Edema (DME)

Active, not recruitingPH IVAlimera Sciencesn=3002024

Recent completions

Trials that read out recently, adding to the completed evidence base.

A Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Patients With Diabetic Macular Edema

CompletedPH I/IIGenentech, Inc.n=3882026

Multi-Center, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of 8 mg Aflibercept in Chinese Participants With Diabetic Macular Edema

CompletedPH IIIBayern=3332026

CompletedPH IVBayern=512025

A Phase 2b, Prospective, Multicenter, Randomized, Double-Masked, Active-Controlled Study to Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With Diabetic Macular Edema

CompletedPH IIUnity Biotechnology, Inc.n=522025

ODYSSEY: A Phase 2b Study of Suprachoroidally Administered CLS-AX in Participants With Neovascular Age-Related Macular Degeneration

CompletedPH IIClearside Biomedical, Inc.n=602024

Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Retinopathy for Subjects Who Completed the 2-Year PANORAMA Trial

CompletedPH IVGreater Houston Retina Researchn=412024

Research activity

7 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time

20142024

Most influential

Lancet (London, England) · 2022 · 578 cites

Effect of Bevacizumab vs Aflibercept on Visual Acuity Among Patients With Macular Edema Due to Central Retinal Vein Occlusion: The SCORE2 Randomized Clinical Trial.

JAMA · 2017 · 164 cites

A single-arm, investigator-initiated study of the efficacy, safety and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration, previously treated with ranibizumab or bevacizumab: 6-month interim analysis.

The British journal of ophthalmology · 2014 · 53 cites

A single-arm, investigator-initiated study of the efficacy, safety, and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration previously treated with ranibizumab or bevacizumab (ASSESS study): 12-month analysis.

Clinical ophthalmology (Auckland, N.Z.) · 2015 · 24 cites

Anti-Vascular Endothelial Growth Factors Protect Retinal Pigment Epithelium Cells Against Oxidation by Modulating Nitric Oxide Release and Autophagy.

Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology · 2017 · 16 cites

Aflibercept in Combination With FOLFIRI as First-line Chemotherapy in Patients With Metastatic Colorectal Cancer (mCRC): A Phase II Study (FFCD 1302).

Clinical colorectal cancer · 2020 · 5 cites

Related drugs

5 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Faricimab

Acts on the same molecular target as Aflibercept, with an overlapping disease area.

Shared target1 shared disease1 shared paper

Adenine

Frequently co-studied with Aflibercept in the research literature.

1 shared paper

Hydrogen Peroxide

Frequently co-studied with Aflibercept in the research literature.

1 shared paper

Nitric Oxide

Frequently co-studied with Aflibercept in the research literature.

1 shared paper

Sirolimus

Frequently co-studied with Aflibercept in the research literature.

1 shared paper

References & data sources

RxNorm (U.S. National Library of Medicine) — drug identity
ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
Europe PMC — research literature
ClinicalTrials.gov — clinical trials
Regulatory event sources are credited in the Regulatory Timeline above.